CAR T Cells: A Living Targeted Drug, With Dr Matt Cooper

In this installment of Teach Me in 10, we're joined by Matt Cooper, co-founder and chief scientific officer at Wugen, Inc. He is also assistant professor of medicine at Washington University. Matt discusses what T cells are and how they can be engineered to recognize cancer cells.

This can be achieved by incorporating a specific receptor – the chimeric antigen receptor (CAR) – which results in the generation of CAR T cells.

“CAR T cells are essentially a living targeted drug,” – Matt Cooper.

Learn more about the key challenges related to engineering CAR T cells, discover ways to enable the broader application of these cells and hear about the development of allogeneic CAR T cells as an “off-the-shelf” treatment for cancer.

For more information on CAR T cells, check out:

Treating Cancer – 5 Types of Immunotherapy

Opinionated Science Episode 14: Cancer Immunotherapy: Vaccines, Viruses and Nobel Prizes

Cancer and the Immune System

Visit the Teach Me in 10 hub page for more < 10 minutes science!